|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1998-2-24
|
|
pubmed:abstractText |
Effective tumor immunity requires recognition of tumor cells coupled with the activation of host effector responses. Fc receptor (FcR) gamma-/- mice, which lack the activating Fc gamma R types I and III, did not demonstrate protective tumor immunity in models of passive and active immunization against a relevant tumor differentiation antigen, the brown locus protein gp75. In wild-type mice, passive immunization with mAb against gp75 or active immunization against gp75 prevented the development of lung metastases. This protective response was completely abolished in FcR gamma-deficient mice. Immune responses were intact in gamma-/- mice because IgG titers against gp75 develop normally in gamma-/- mice immunized with gp75. However, uncoupling of the Fc gamma R effector pathway from antibody recognition of tumor antigens resulted in a loss of protection against tumor challenge. These data demonstrate an unexpected and critical role for FcRs in mediating tumor cytotoxicity in vivo and suggest that enhancement of Fc gamma R-mediated antibody-dependent cellular cytotoxicity by inflammatory cells is a key step in the development of effective tumor immunotherapeutics.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/9435247-1794178,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9435247-2324688,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9435247-6643767,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9435247-7252406,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9435247-7595233,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9435247-7621075,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9435247-7836932,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9435247-7887661,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9435247-8006576,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9435247-8066448,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9435247-8164027,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9435247-8205563,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9435247-8313472,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9435247-8546004,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9435247-8706052,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9435247-8839236,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9435247-8859727,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9435247-8902386,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9435247-8931683,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9435247-8962137,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9435247-8976192,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9435247-9039776,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9435247-9118024,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9435247-9278297,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9435247-9816138
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Oxidoreductases,
http://linkedlifedata.com/resource/pubmed/chemical/Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Fc,
http://linkedlifedata.com/resource/pubmed/chemical/Tyrp1 protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/tyrosinase-related protein-1
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0027-8424
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
20
|
|
pubmed:volume |
95
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
652-6
|
|
pubmed:dateRevised |
2010-6-10
|
|
pubmed:meshHeading |
pubmed-meshheading:9435247-Animals,
pubmed-meshheading:9435247-Antibodies, Monoclonal,
pubmed-meshheading:9435247-Antigens, Neoplasm,
pubmed-meshheading:9435247-Immunity,
pubmed-meshheading:9435247-Immunization, Passive,
pubmed-meshheading:9435247-Melanoma, Experimental,
pubmed-meshheading:9435247-Membrane Glycoproteins,
pubmed-meshheading:9435247-Mice,
pubmed-meshheading:9435247-Mice, Inbred C57BL,
pubmed-meshheading:9435247-Oxidoreductases,
pubmed-meshheading:9435247-Proteins,
pubmed-meshheading:9435247-Receptors, Fc,
pubmed-meshheading:9435247-Vaccination
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Fc receptors are required in passive and active immunity to melanoma.
|
|
pubmed:affiliation |
Laboratory of Molecular Genetics and Immunology, Rockefeller University, New York, NY, USA. clynesr@rockvax.rockefeller.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
